Protocol Ledger

NCT06933472 · Phase III · RECRUITING

A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China

Interventional Phase III clinical trial protocol NCT06933472 sponsored by Alebund Pharmaceuticals in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-06-13 Enrollment: 264 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06933472
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)264 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06933472
Protocol FieldVerified Registry Value
NCT IdentifierNCT06933472
Consolidated Lead SponsorAlebund Pharmaceuticals
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment264 participants (ESTIMATED)
Registered Start Date2025-06-13
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06933472
Hospital Research SiteLocationSite Profile
Peking University First HospitalBeijing, ChinaOpen Hospital Dossier ->
The First Affiliated Hospital of Xiamen UniversityXiamen, ChinaOpen Hospital Dossier ->
Henan Provincial People's HospitalZhengzhou, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI